[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337249-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337249-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-analysis-of-lmnb2-in-pan-cancer-and-identification-of-its-biological-role-in-sarcoma","Comprehensive analysis of LMNB2 in pan-cancer and identification of its biological role in sarcoma","","Sarcoma (SARC), a mesenchymal tumor with limited responsiveness to systemic therapy, requires reliable biological markers to predict prognosis and progression. This study integrates Cancer Genome Atlas (TCGA) and GTEx to evaluate LMNB2 expression across cancer types, then applies Kaplan-Meier survival analyses for overall survival and disease-free survival. Associations between LMNB2 expression and immune infiltration, MSI, and TMB are assessed, alongside GO/KEGG enrichment. Functional assays, including MTT and flow cytometry, further test proliferation and cell-cycle effects, with western blot confirming cyclinD1 and cyclinE1 regulation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-analysis-of-lmnb2-in-pan-cancer-and-identification-of-its-biological-role-in-sarcoma/337249/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-analysis-of-lmnb2-in-pan-cancer-and-identification-of-its-biological-role-in-sarcoma/337249.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is LMNB2 being studied in sarcoma?","Question",{"text":63,"@type":64},"Sarcoma often responds poorly to systemic therapy, so biological markers are needed to better predict prognosis and progression. LMNB2 has been implicated in cancer development, but its specific role in sarcoma remains insufficiently understood.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was LMNB2 expression analyzed across cancers?",{"text":68,"@type":64},"The study mined TCGA to compare LMNB2 expression in cancer versus paracancerous or normal tissues across multiple cancer types. It also examined associations between LMNB2 expression levels and survival outcomes across cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What functional evidence supports LMNB2’s role in sarcoma cell behavior?",{"text":72,"@type":64},"Downregulating LMNB2 impaired proliferation and altered cell-cycle distribution. Mechanistically, LMNB2 was reported to regulate cyclinD1 and cyclinE1, with additional protein expression assessed using western blot.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337249,1790182088,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","[www.aging-us.com](www.aging-us.com) AGING 2025, Vol. 17, No. 1  \nResearch Paper  \nComprehensive analysis of LMNB2 in pan-cancer and identification of its biological role in sarcoma  \nYonghui Guo1,2,*, Min Zhang3,*, Yingrui Luo4, Yingshi Li5, Yanxia Xu6, Nisha Wang7  \n1 Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China  \n2Guangdong Provincial Clinical Research Center for Laboratory Medicine, Guangzhou, Guangdong Province, China 3GuangDong Second Province General Hospital, Neurosurgery Department (MH), Guangzhou, Guangdong Province, China  \n4Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, China  \n5Southern Medical University, Guangzhou, Guangdong Province, China  \n6 Department of Radiation Oncology, Zhuhai People’s Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, Guangdong Province, China  \n7 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, China  \n*Equal contribution  \nCorrespondence to: Yanxia Xu, Nisha Wang; email: [1032138910@qq.com](1032138910@qq.com), [https://orcid.org/0009-0002-9465-2140](https://orcid.org/0009-0002-9465-2140); [nisha@smu.edu.cn](nisha@smu.edu.cn)  \nKeywords: LMNB2, pan-cancer, sarcoma, prognosis, cell proliferation  \nReceived: September 18, 2023 Accepted: December 27, 2023 Published: July 8, 2024  \nCopyright: © 2024 Guo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nBackgrounds: Sarcoma (SARC) is a mesenchymal tumor which often responds poorly to systemic therapy. It is therefore important to look for possible biological markers that could tell the prognosis and the progression of SARC. Methods: A combined evaluation of the Cancer Genome Atlas (TCGA) and genotypic tissue expression (GTEx) portal was used to analyzeLMNB2 expression level in different types of cancer. Kaplan-Meier survival analysis was performed to examine LMNB2 predictive value in over-all survival rate and disease-free survival rate. The association among LMNB2 expression level and immune cell infiltration, microsatellite instability (MSI) and tumor mutational burden (TMB) were analyzed. GO and KEGG enrichment analysis were performed to predicate LMNB2 biological functions. The biological function of LMNB2 was estimated by MTT and flow cytometry assay. Additionally, western blot assay was used to examine protein expression levels.  \nResults: Increased LMNB2 expression was related with worsened cancer type-dependent survival. A relation between LMNB2 expression levels and immune cell infiltration was found. GO and KEGG enrichment analysis indicated that LMNB2 was involved in a series of pathways. Biology function assays revealed that downregulation of LMNB2 impaired proliferation and cell cycle distribution. At the mechanical level, LMNB2 acts as a regulator of cyclinD1 and cyclinE1 .  \nConclusions: Altogether, these data suggest that LMNB2 may serve as a tumor promoter and could be a possible target for cancer therapy.  \nINTRODUCTION  \nSarcomas (SARC) form a heterogeneous cancer population from mesenchymal cell sources consisting  \nof more than 70 malignant primary tumors [1] . The most common sarcomas start in the bone and soft tissue and are responsible for approximately 19 to 21% of cancer-related deaths in children and young  \n203  \nadults [2, 3] . Standard treatment options include neoadjuvant chemotherapy combined with surgery and/or radiotherapy [4] . However, new treatments are needed because the overall survival rate of patients with metastatic or recurrent diseases is less than 20%  \n[5] . In the last two decades, the understanding of the molecular path","cbCaisoiVpo4siQV","https://ap.wps.com/l/cbCaisoiVpo4siQV","pdf",3248593,14,"English","# Abstract\n## Background and Methods\n## Results\n## Conclusions\n# Introduction\n## Sarcoma overview and clinical need\n## LMNB2 background and research rationale\n# Results\n## Comprehensive analysis of LMNB2 in pan-cancers","[{\"question\":\"Why is LMNB2 being studied in sarcoma?\",\"answer\":\"Sarcoma often responds poorly to systemic therapy, so biological markers are needed to better predict prognosis and progression. LMNB2 has been implicated in cancer development, but its specific role in sarcoma remains insufficiently understood.\"},{\"question\":\"How was LMNB2 expression analyzed across cancers?\",\"answer\":\"The study mined TCGA to compare LMNB2 expression in cancer versus paracancerous or normal tissues across multiple cancer types. It also examined associations between LMNB2 expression levels and survival outcomes across cancers.\"},{\"question\":\"What functional evidence supports LMNB2’s role in sarcoma cell behavior?\",\"answer\":\"Downregulating LMNB2 impaired proliferation and altered cell-cycle distribution. Mechanistically, LMNB2 was reported to regulate cyclinD1 and cyclinE1, with additional protein expression assessed using western blot.\"}]","Comprehensive analysis of LMNB2 in pan-cancer and identification of its biological role in sarcoma | PDF",1790018333,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48169e7160b481db2e9b6ef03c86a8a7.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08bd24549b4240cfdb922a217b3ab855.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce523dac00e2b3662da9e6e7e8ccf58c.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7cda8fe84677f637ae9b79a24c02e8a.webp",980,1268]